Active surveillance up in multidisciplinary prostate CA care

August 1, 2012
Active surveillance up in multidisciplinary prostate CA care
Men with low-risk prostate cancer are more likely to pursue active surveillance when seen at a multidisciplinary prostate cancer clinic rather than when they see individual specialists in sequential settings, according to a study published online July 30 in the Journal of Clinical Oncology.

(HealthDay) -- Men with low-risk prostate cancer are more likely to pursue active surveillance when seen at a multidisciplinary prostate cancer clinic rather than when they see individual specialists in sequential settings, according to a study published online July 30 in the Journal of Clinical Oncology.

To examine the factors associated with active surveillance in patients with low-risk prostate cancer, Ayal A. Aizer, M.D., M.H.S., of Massachusetts General Hospital in Boston, and colleagues conducted a study involving 701 men who were either treated at a multidisciplinary prostate cancer clinic with a team consisting of an urologist and radiation and medical oncologists, or who saw individual specialists sequentially.

The researchers found the crude rates of active surveillance to be almost double for those seen in the multidisciplinary clinic compared with those seen by individual physicians (43 versus 22 percent), while the proportion treated with or was reduced by about 30 percent. The pursuit of active surveillance was significantly associated with consultation at a multidisciplinary clinic (odds ratio [OR], 2.15), older age (OR, 1.09), unmarried status (OR, 1.66), increased Charlson comorbidity index (OR, 1.37), and fewer positive cores (OR, 0.92).

"In conclusion, our study indicates that multidisciplinary care is associated with a significantly increased rate of active surveillance in men with low-risk , a finding that may have an important clinical, social, and economic impact," the authors write.

Explore further: Active surveillance cost-effective for prostate cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Active surveillance cost-effective for prostate cancer

July 13, 2012
(HealthDay) -- In a theoretical cohort of 120,000 men, selecting active surveillance for prostate cancer results in considerable cost savings at five and 10 years of follow-up, compared with immediate treatment, according ...

New approach to prostate cancer care draws patients with riskiest disease

January 5, 2012
(Medical Xpress) -- In choosing where they get treatment, prostate cancer patients tend to opt for a major cancer center if they have severe disease, but stick closer to home for less complicated cases, even when offered ...

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

JGE
not rated yet Aug 15, 2012
Now known to most scientific support morbildad caused by the procedures to diagnose and treat prostate cancer, active surveillance is a well indicated for selected patients. We need a report or report of consensus which categorically its indication and scope

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.